We are counting down to BAUS 2019 in Glasgow next week.
Will you be in Glasgow this year? If so, visit us on Stand 445 between 24-26 June to find out more about the EMDA® Bladder Cancer Treatment.
EMDA® has been proven to significantly prolong the disease-free interval and reduce the risk of recurrence in high and intermediate-risk patients with NMIBO (non-muscle invasive bladder cancer).
Following an interventional procedure overview of the EMDA® (Electromotive Drug Administration) treatment in June 2018, NICE issued updated guidance for clinicians in England and Wales 
on 30 January 2019 and called for EMDA® to be used in research programmes as a treatment for bladder cancer.
There are currently studies underway at several Urology clinics including Guy’s & St Thomas’ NHS Foundation Trust in London and Salisbury District Hospital. Contact us to find a clinic near you.
For more information on EMDA® or to arrange a meeting at BAUS 2019, please contact Robin Luper on +44 (0)1234-888955 or by email via info@js-group.global.
Further information
